Ihsan Fadilah_22010110120066_Bab8KTI
Transcript of Ihsan Fadilah_22010110120066_Bab8KTI
50 !
!
DAFTAR PUSTAKA
1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third
universal definition of myocardial infarction. Circulation [Internet]. 2012 [cited
2014 Feb 17]; 126:2012-35. Available from:
http://circ.ahajournals.org/content/126/16/2020.full.pdf+html
2. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Blackett KN, et
al. World Health Organization definition of myocardial infarction: 2008-09
revision. International Journal of Epidemiology [Internet]. 2011 [cited 2014 Feb
17]; 40:139-46. Available from:
http://ije.oxfordjournals.org/content/40/1/139.full.pdf+html
3. Global status report on noncommunicable diseases 2010. Geneva (Switzerland):
World Health Organization; 2011 [cited 2014 Feb 17]. Available from:
http://www.who.int/nmh/publications/ncd_report_full_en.pdf
4. Rosamod WD, Chambless LE, Folsom AR, Cooper LS, Conwill DE, Clegg L, et
al. Trends in the incidence of myocardial infarction and in mortality due to
coronary heart disease, 1987 to 1994. N Engl J Med [Internet]. 1998 [cited 2014
Feb 17]; 339:861-7. Available from:
http://www.nejm.org/doi/full/10.1056/NEJM199809243391301
5. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in
coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the
Framingham Heart Study. Circulation [Internet]. 2004 [cited 2013 Feb 17];
110:522-7. Available from: http://circ.ahajournals.org/content/110/5/522.full
6. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart
disease and stroke statistics–2007 update: a report from the American Heart
Association Statistics Commitee and Stroke Statistics Subcommitee. Circulation
[Internet]. 2007 [cited 2014 Feb 17]; 115:e69-171. Available from:
http://circ.ahajournals.org/content/115/5/e69.full
7. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left
ventricular systolic dysfunction after acute myocardial infarction: prevalence,
51 !
! !
51
clinical characteristics, and prognostic importance. Am J Cardiol [Internet]. 2006
[cited 2014 Feb 17]; 97:13F-25F. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16698331
8. Hellerman JP, Jacobsen SJ, Redfield MM, Reeder GS, Weston SA, Roger VL.
Heart failure after myocardial infarction: clinical presentation and survival. The
European Journal of Heart Failure [Internet]. 2005 [cited 2014 Feb 17]; 7:119-25.
Available from: http://eurjhf.oxfordjournals.org/content/7/1/119.full.pdf+html
9. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–Concepts and clinical
implications: a consensus paper from an international forum on cardiac
remodeling. J Am Coll Cardiol [Internet]. 2000 [cited 2014 Feb 17]; 35(3):569-
82.
10. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction:
pathophysiology and therapy. Circulation [Internet]. 2000 [cited 2014 Feb 17];
101:2981-8. Available from: https://circ.ahajournals.org/content/101/25/2981.full
11. Rame JE, Dries DL. Heart failure and cardiac hypertrophy. Current Treament
Options in Cardiovascular Medicine [Internet]. 2007 [cited 2014 Feb 18];
9(4):289-301. Available from:
http://link.springer.com/article/10.1007%2Fs11936-007-0024-3
12. Ishii H, Amano T, Matsubara T, Murohara T. Pharmacological intervention for
prevention of left ventricular remodeling and improving prognosis in myocardial
infarction. Circulation [Internet]. 2008 [cited 2014 Feb 22]; 118:2710-18.
Available from: https://circ.ahajournals.org/content/118/25/2710.full.pdf+html
13. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, et
al. Long-term trends in the incidence of heart failure after myocardial infarction.
Circulation [Internet]. 2008 [cited 2014 Feb 22]; 118(20):2057-62. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/18955667
14. Cicero AFG, Tartagni E, Ertek S. Metformin and its clinical use: new insights for
an old drug in clinical practice. Arch Med Sci [Internet]. 2012 [cited 2014 Feb
18]; 8(5):907-17. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/23185203
52 !
! !
52
15. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect
of metformin treatment on multiple cardiovascular disease risk factors in patients
with type 2 diabetes mellitus. Metabolism [Internet]. 2004 [cited 2014 Feb 18];
53(2):159-64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14767866
16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-
glucose control with metformin on complications in overweight patients with type
2 diabetes (UKPDS 34). Lancet [Internet]. 1998 [cited 2014 Feb 18];
352(9139):1558. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9742977
17. Holman RR, Paul SK, Bethel MA, Mattews DR, Neil HA. Ten year follow-up of
intensive glucose control in type 2 diabetes. N Engl J Med [Internet]. 2008 [cited
2014 Feb 14]; 359(15): 1577-89. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18784090
18. Chan AM, Soltys CM, Young ME, Proud CG, Dyck JR. Activation of AMP-
activated protein kinase inhibits protein synthesis associated with hypertrophy in
the cardiac myocyte. J Biol Chem [Internet]. 2004 [cited 2014 Feb 18];
279(31):32771-9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/15159410
19. Fu YN, Xiao H, Ma XW, Jiang SY, Xu M, Zhang YY. Metformin attenuates
pressure overload-induced cardiac hypertrophy via AMPK activation. Acta
Pharmacol Sin [Internet]. 2011 [cited 2014 Feb 18]; 32(7):879-87. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/21552292
20. Cha HN, Choi JH, Kim YW, Kim JY, Ahn MW, Park SY. Metformin inhibits
isoproterenol-induced cardiac hypertrophy in mice. Korean J Physiol Pharmacol
[Internet]. 2010 [cited 2014 Feb 18]; 14(6):377-84. Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034117
21. Wong AK, Howie J, Petrie JR, Lang CC. AMP-activated protein kinase pathway:
a potential therapeutic target in cardiometabolic disease. Clin Sci (Lond)
[Internet]. 2009 [cited 2014 Feb 23]; 116(8):607-20. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/19275766
22. Beauloye C, Bertrand L, Horman S, Hue L. AMPK activation, a preventive
therapeutic target in the transition from cardiac injury to heart failure. Cardiovasc
53 !
! !
53
Res [Internet]. 2011 [cited 2014 Feb 23]; 90(2):224-33. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21285292
23. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Sillje HH, de Boer
RA. Metformin improves cardiac function in a nondiabetic rat model of post-MI
heart failure. Am J Physiol Heart Circ Physiol [Internet]. 2011 [cited 2014 Feb
18]; 301(2):H459-68. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21572014
24. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, et al. Activation
of AMP-activated protein kinase by metformin improves left ventricular function
and survival in heart failure. Circ Res [Internet]. 2009 [cited 2014 Feb 18];
104(3):403-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19096023
25. Benes J, Kazdova L, Drahota Z, Houstek J, Medrikova D, Kopecky J, et al. Effect
of metformin therapy on cardiac function and survival in a volume-overload
model of heart failure in rats. Clin Sci (Lond) [Internet]. 2011 [cited 2014 Feb
21]; 121(1):29-41. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21275906
26. Naik H, Sabatine MS, Lilly LS. Ischemic heart disease. In: Lilly LS, editor.
Pathophysiology of heart disease : a collaborative project of medical students and
faculty. 4th ed. Baltimore/Philadelphia: Lippincott Williams & Wilkins; 2007. p.
141-69.
27. Gao E, Koch WJ. A novel and efficient model of coronary artery ligation in
mouse. Methods Mol Biol [Internet]. 2013[cited 2014 Feb 21]; 1037:299-311.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24029943
28. Gao E, Lei YH, Shang X, Huang ZM, Zuo L, Buocher M, et al. A novel and
efficient model of coronary artery ligation and myocardial infarction in the mouse.
Circ Res [Internet]. 2010 [cited 2014 Feb 21]. 107(12):1445-53. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20966393
29. Patten RD, Hall-Porter MR. Small animal models of heart failure–Developmet of
novel therapies, past, and present. Circ Heart Fail [Internet]. 2009 [cited 2014 Mar
17]; 2:138-44. Available from:
http://circheartfailure.ahajournals.org/content/2/2/138.full
54 !
! !
54
30. Gaspard GJ, Pasumarthi KB. Quantification of cardiac fibrosis by colour-
subtractive computer-assisted image analysis. Clin Exp Pharmacol Physiol
[Internet]. 2008 [cited 2014 Feb 21]. 35:679-86. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/18387083
31. Zhang GX, Ohmori K, Nagai Y, Fujisawa Y, Nishiyama A, Abe Y, Kimura S.
Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative
stress in mice. J Mol Cell Cardiol [Internet]. 2007 [cited 2014 Feb 21]. 42(4):804-
11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17350036
32. Engle SK, Jordan WH, Pritt ML, Chiang AY, Davis MA, Zimmermann JL, et al.
Qualification of cardiac troponin I concentration in mouse serum using
isoproterenol and implementation in pharmacology studies to accelerate drug
development. Toxicol Pathol [Internet]. 2009 [cited 2014 May 21]; 37:617-28.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19549929
33. De S, Adhikari S, Devasagayam TPA. Cardioprotective effects of an
aminothiazole compound on isoproterenol-induced myocardial injury in mice.
Cell Biochem Biophys [Internet]. 2013 [cited 2014 May 21]; 67(2):287-95.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21948074
34. Rona G. Cathecolamine cardiotoxicity. J Mol Cell Cardiol [Internet]. 1985 [cited
2014 Feb 21]; 17(4):291-306. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/3894676
35. Upaganlawar A, Gandhi H, Balaraman R. Isoproterenol induced myocardial
infarction: protective role of natural products. J Pharmacol Toxicol [Internet].
2011 [cited 2014 Feb 21]. 6:1-17. Available from:
http://scialert.net/abstract/?doi=jpt.2011.1.17
36. Soraya H, Khorrami A, Garjani A, Malek-Dizaji N, Garjani A. Acute treatment
with metformin improves cardiac function following isoproterenol-induced
myocardial infarction in rats. Pharmacol Rep [Internet]. 2012 [cited 2014 Feb 21];
64(6):1476-84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23406758
37. Brooks WW, Conrad CH. Isoproterenol-induced myocardial injury and diastolic
dysfunction in mice: structural and functional correlates. Comp Med [Internet].
55 !
! !
55
2009 [cited 2014 Feb 21]; 59(4):339-43. Available:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779208/
38. Wang Y, Wisloff U, Kemi OJ. Animals models in the study of exercise-induced
cardiac hypertrophy. Physiol Res [Internet]. 2010 [cited 2014 Feb 8]; 59(5):633-
44. Available from: http://www.biomed.cas.cz/physiolres/pdf/prepress/931928.pdf
39. Labuzek K, Liber S, Gabryel B, Okopien B. Metformin has adenosine-
monophosphate activated protein kinase (AMPK)-independent effects on LPS-
stimulated rat primary microglial cultures. Pharmacol Rep [Internet]. 2010 [cited
2014 Feb 23]; 62(5):827-48. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21098866
40. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular
and molecular mechanisms of metformin: an overview. Clin Sci (Lond) [Internet].
2012 [cited 2014 Feb 23]; 122(6):253-70. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22117616
41. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular
energy. Nat Rev Mol Cell Biol [Internet]. 2007 [cited 2014 Feb 23]; 8(10):774-85.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/17712357
42. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol
Toxicol [Internet]. 2007 [cited 2014 Feb 23]; 47:185-210. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16879084
43. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, et al.
Phosphorylation and activation of heart PFK-2 by AMPK has a role in the
stimulation of glycolysis during ischemia. Curr Biol [Internet]. 2000 [cited 2014
Feb 23]; 10(20):1247-55. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/11069105
44. Hue L, Rider MH. The AMP-activated protein kinase: more than an energy
sensor. Essays Biochem [Internet]. 2007 [cited 2014 Feb 23]; 43:121-137.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/17705797
45. Hou X, Song J, Li XN, Zhang L, Wang X, Chen L, et al. Metformin reduces
intracellular reactive oxygen species levels by upregulating expression of the
antioxidant thioredoxin via the AMPK-FOXO3 pathway. Biochem Biophys Res
56 !
! !
56
Commun [Internet]. 2010 [cited 2014 Feb 23]; 396:199-205. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20398632
46. Bertrand L, Horman S, Beauloye C, Vanocershelde JL. Insulin signalling in the
heart. Cardiovasc Res [Internet]. 2008 [cited 2014 Feb 23]; 79:238-48. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/18390897
47. Proud CG. Signalling to translation: how signal transduction pathways control the
protein synthetic machinery. Biochem J [Internet]. 2007 [cited 2014 Feb 23];
403:217-34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17376031
48. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, et al.
Activation of AMP-activated protein kinase leads to the phosphorylation of
elongation factor 2 and an inhibition of protein synthesis. Curr Biol [Internet].
2002 [cited 2014 Feb 23]; 12:1419-23. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/12194824
49. Lee HH, Yeh CH, Chen YT, Chi TC, Cheng JT, Lo SH. Effects of metformin on
rosiglitazone-induced cardiac hypertrophy in mice. Biol Pharm Bull [Internet].
2010 [cited 2014 Feb 23]; 33(9):1506-10. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20823565
50. Charan J, Kantharia ND. How to calculate sample size in animal studies? J
Pharmacol Pharmacother [Internet]. 2013 [cited 2014 Feb 7]; 4(4):303-6.
Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826013/#!po=43.7500
51. National Research Council of the National Academies. Guide for the care and use
of laboratory animals. 8th ed [Internet]. Washington, D.C.: The National
Academies Press; 2011 [cited 2014 Feb 7]. Available from:
http://grants.nih.gov/grants/olaw/Guide-for-the-care-and-use-of-laboratory-
animals.pdf
52. McConnell EL, Basit AW, Murdan S. Measurements of rat and mouse
gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo
experiments. J Pharm Pharmacol [Internet]. 2008 [cited 2014 Mar 17]; 60(1):63-
70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18088506
57 !
! !
57
53. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic
cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has
no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos
[Internet]. 2012 [cited 2014 Mar 17]; 40(6):1170-7. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/22407892
54. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Furlong TJ, et al. Clinical
pharmacokinetics of metformin. Clin Pharmacokinet [Internet]. 2011 [cited 2014
Mar 17]; 50(2):81-98. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21241070
55. Khatua TN, Padiya R, Karnewar S, Kuncha M, Agawane SB, Kotamraju, et al.
Garlic provides protection to mice heart against isoproterenol-induced oxidative
damage: role of nitric oxide. Nitric Oxide [Internet]. 2012 [cited 2014 Feb 5];
27(1):9-17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22484451
56. Gupta P, Kanwal A, Putcha UK, Bulani Y, Sojitra B, Khatua TN, et al.
Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced
myocardial necrosis: a new therapeutic implication. Jornal of Translational
Medicine [Internet]. 2013 [cited 2014 Feb 8]; 11:80. Available from:
http://www.translational-medicine.com/content/pdf/1479-5876-11-80.pdf
57. Murugesan M, Revathi R, Manju V. Cardioprotective effect of fenugreek on
isoproterenol-induced myocardial infarction in rats. Indian J Pharmacol [Internet].
2011 [cited 2014 Feb 8]; 43:516-9. Available from: http://www.ijp-
online.com/article.asp?issn=0253-
7613;year=2011;volume=43;issue=5;spage=516;epage=519;aulast=Murugesan
58. AVMA Guidelines for the euthanasia of an animals: 2013 edition [Internet].
Schaumburg: American Veterinary Medical Association; 2013 [cited 2014 Feb 7].
Available from: https://www.avma.org/kb/policies/documents/euthanasia.pdf
59. Heart dissection [Internet]. Oxford (UK): European Mouse Phenotyping Resource
of Standardised Screens (EMPReSS); 2004 [cited 2014 Feb 8]. Available from:
http://www.mousebook.org/sops/020_001_heart_dissection_080407.pdf
58 !
! !
58
60. Mouse Morphometry [Internet]. Animal Models of Diabetic Complications
Consortium (AMDCC); 2004 [cited 2014 Feb 8]. Available from:
https://www.diacomp.org/shared/showFile.aspx?doctypeid=3&docid=47
61. Collagen–Masson’s Trichrome stain (TRI) [Internet]. Georgia (USA): The
Internet Pathology Laboratory for Medical Education; date unknown [cited 2014
Feb 8]. Available from:
http://library.med.utah.edu/WebPath/HISTHTML/MANUALS/MASSONS.PDF
62. Helms SA, Azhar G, Zuo C, Theus SA, Bartke A, Wei JY. Smaller cardiac cell
size and reduced extra-cellular collagen might be beneficial for hearts of Ames
dwarf mice. Int J Biol Sci [Internet]. 2010 [cited 2014 Feb 8]; 6(5):475-90.
Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935670/?report=classic
63. Teori sederhana prosedur pemilihan uji hipotesis. In: Dahlan MS. Statistik untuk
kedokteran dan kesehatan. Jakarta (Indonesia): Salemba Medika; 2011. p. 1-29.
64. Statistik deskriptif. In: Dahlan MS. Statistik untuk kedokteran dan kesehatan.
Jakarta (Indonesia): Salemba Medika; 2011. p. 31-60.
65. Uji hipotesis komparatif variabel numerik lebih dari dua kelompok. In: Dahlan
MS. Statistik untuk kedokteran dan kesehatan. Jakarta (Indonesia): Salemba
Medika; 2011. p. 87-128.
66. Analisis kesintasan (Survival analysis). In: Sastroasmoro S, Ismael S. Dasar-dasar
metodologi penelitian klinis. Jakarta (Indonesia): Sagung Seto; 2011. p.245-63.
67. Hoggatt A, Hoggatt J, Honerlaw M, Pelus LM. A spoonful of sugar helps the
medicine go down: a novel technique to improve oral gavage in mice. J Am Assoc
Lab Anim Sci [Internet]. 2010 [cited 2014 Jul 14]; 49(3):329-34Available from:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2877306/?report=classic
68. Wu JC, Nasseri BA, Bloch KD, Picard MH, Scherrer-Crosbie M. Influence of sex
on ventricular remodeling after myocardial infarction in mice. J Am Soc
Echocardiogr [Internet]. 2003 [cited 2014 Jul 14]; 16(11):1158-62. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/14608287
69. Van Loo PLP, Van Zutphen LFM, Baumans V. Male management: coping with
aggression problems in male laboratory mice. Lab Anim [Internet]. 2003 [cited
59 !
! !
59
2014 Jul 14]; 37:300-13. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/14599305
70. Kaliste-Korhonen E, Eskola S. Fighting in NIH/S male mice: consequence for
behaviour in resident-intruder tests and physiological parameters. Lab Anim
[Internet]. 2000 [cited 2014 Jul 14]; 34:189-98. Available from:
http://lan.sagepub.com/content/34/2/189.full.pdf
60 !
!
LAMPIRAN
Lampiran 1. Ethical Clearance
61 !
!
Lampiran 2. Izin Penelitian
62 !
!
Lampiran 3. Sertifikat Hewan Coba
63 !
!
Lampiran 4. Dokumentasi Penelitian
tempat pemeliharaan hewan coba
penyondean pemberian makan dan minum ad libitum
pengukuran panjang tibia pembedahan
64 !
!
Lampiran 5. Luaran Analisis Program Statistik
Descriptives Luas Penampang Kardiomiosit
N Mean Std.
Deviation Std. Error 95% Confidence Interval for Mean
Minimum Maximum Lower Bound Upper Bound ISO 9 236.18764 63.449817 21.149939 187.41479 284.95849 115.925 330.790 MET+ISO 11 166.65958 39.299550 11.849260 140.25778 193.06137 99.949 234.393 MET 11 156.25721 44.672729 13.469335 126.24566 186.26876 103.179 233.819 K 11 141.87973 23.092445 6.962634 126.36601 157.39344 105.358 183.130 Total 42 172.34384 54.779943 8.452729 155.27321 189.41448 99.949 330.790
Tests of Normality
Group
Kolmogorov-Smirnova Shapiro-Wilk Statistic df Sig. Statistic df Sig. Luas Penampang Kardiomiosit
ISO .199 9 .200* .966 9 .859 MET+ISO .145 11 .200* .981 11 .971 MET .197 11 .200* .915 11 .279 K .171 11 .200* .957 11 .735
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction
65 !
! !
65
Test of Homogeneity of Variances Luas Penampang Kardiomiosit
Levene Statistic df1 df2 Sig. 2.026 3 38 .127
ANOVA
Luas Penampang Kardiomiosit
Sum of Squares df Mean Square F Sig. Between Groups 50093.808 3 16697.936 8.699 .000 Within Groups 72940.719 38 1919.493 Total 123034.526 41
BERAT BADAN HARI KE-1
Descriptives Berat Badan (pre)
N Mean Std.
Deviation Std. Error 95% Confidence Interval for Mean
Minimum Maximum Lower Bound Upper Bound ISO 11 27.18 1.537 .464 26.15 28.21 25 30 MET+ISO 11 27.91 2.982 .899 25.91 29.91 23 32 MET 11 28.82 2.359 .711 27.23 30.40 25 34 K 11 27.36 1.859 .560 26.11 28.61 25 31 Total 44 27.82 2.265 .341 27.13 28.51 23 34
66 !
! !
66
Tests of Normality
Group Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig. Berat Badan (pre)
ISO .234 11 .096 .924 11 .351 MET+ISO .123 11 .200* .953 11 .679 MET .197 11 .200* .947 11 .602 K .184 11 .200* .900 11 .187
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction
Test of Homogeneity of Variances Berat Badan (pre)
Levene Statistic df1 df2 Sig. 1.861 3 40 .152
ANOVA
Berat Badan (pre)
Sum of Squares df Mean Square F Sig. Between Groups 17.818 3 5.939 1.172 .332 Within Groups 202.727 40 5.068 Total 220.545 43
67 !
!
Multiple Comparisons Dependent Variable: Luas Penampang Kardiomiosit
LSD
(I) Group (J) Group Mean
Difference (I-J) Std. Error Sig. 95% Confidence Interval
Lower Bound Upper Bound ISO MET+ISO 69.527065* 19.692036 .001 29.66262 109.39151
MET 79.929429* 19.692036 .000 40.06499 119.79387 K 94.306914* 19.692036 .000 54.44247 134.17136
MET+ISO ISO -69.527065* 19.692036 .001 -109.39151 -29.66262 MET 10.402363 18.681506 .581 -27.41637 48.22109 K 24.779848 18.681506 .193 -13.03888 62.59858
MET ISO -79.929429* 19.692036 .000 -119.79387 -40.06499 MET+ISO -10.402363 18.681506 .581 -48.22109 27.41637 K 14.377485 18.681506 .446 -23.44125 52.19622
K ISO -94.306914* 19.692036 .000 -134.17136 -54.44247 MET+ISO -24.779848 18.681506 .193 -62.59858 13.03888 MET -14.377485 18.681506 .446 -52.19622 23.44125
*. The mean difference is significant at the 0.05 level.
68 !
!
Case Processing Summary: Survival
Group Total N N of Events Censored
N Percent K 11 0 11 100.0%
ISO 11 2 9 81.8% MET 11 0 11 100.0%
MET+ISO 11 0 11 100.0% Overall 44 2 42 95.5%
Overall Comparisons
Chi-Square df Sig. Log Rank (Mantel-Cox) 6.292 3 .098 Breslow (Generalized Wilcoxon) 6.286 3 .099 Tarone-Ware 6.289 3 .098 Test of equality of survival distributions for the different levels of Group.
69 !
!
BERAT BADAN HARI KE-28 Descriptives
Group Statistic Std. Error Berat Badan (post) ISO Mean 26.56 .766
95% Confidence Interval for Mean Lower Bound 24.79 Upper Bound 28.32
5% Trimmed Mean 26.51 Median 27.00 Variance 5.278 Std. Deviation 2.297 Minimum 23 Maximum 31 Range 8 Interquartile Range 3 Skewness .386 .717 Kurtosis 1.172 1.400
MET+ISO Mean 28.27 .935 95% Confidence Interval for Mean Lower Bound 26.19
Upper Bound 30.36 5% Trimmed Mean 28.03 Median 27.00 Variance 9.618 Std. Deviation 3.101 Minimum 25 Maximum 36 Range 11 Interquartile Range 4 Skewness 1.729 .661 Kurtosis 3.375 1.279
MET Mean 26.18 1.016 95% Confidence Interval for Mean Lower Bound 23.92
Upper Bound 28.45 5% Trimmed Mean 26.15 Median 26.00 Variance 11.364 Std. Deviation 3.371 Minimum 22 Maximum 31 Range 9 Interquartile Range 7 Skewness -.096 .661 Kurtosis -1.706 1.279
K Mean 26.09 .780 95% Confidence Interval for Mean Lower Bound 24.35
Upper Bound 27.83 5% Trimmed Mean 26.10 Median 26.00 Variance 6.691 Std. Deviation 2.587 Minimum 22 Maximum 30 Range 8 Interquartile Range 5 Skewness .387 .661 Kurtosis -.646 1.279
70 !
!
Tests of Normality
Group Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig. Berat Badan (post) ISO .201 9 .200* .940 9 .581
MET+ISO .262 11 .033 .830 11 .023 MET .253 11 .048 .869 11 .076 K .241 11 .073 .912 11 .259
Tests of Normality
Group Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig. Transformasi data BB (post) dengan fungsi LG10
ISO .196 9 .200* .946 9 .643 MET+ISO .245 11 .063 .865 11 .067 MET .255 11 .045 .864 11 .065 K .224 11 .131 .924 11 .349
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction
71 !
! !
71
Test of Homogeneity of Variances BB (post) yang ditransformasi
Levene Statistic df1 df2 Sig. 1.394 3 38 .259
ANOVA
BB (post) yang ditransformasi
Sum of Squares df Mean Square F Sig. Between Groups .009 3 .003 1.375 .265 Within Groups .081 38 .002
Total .090 41
72 !
!
Descriptives
Berat Jantung (BJ)
N Mean Std.
Deviation Std. Error 95% Confidence Interval for Mean
Minimum Maximum Lower Bound Upper Bound ISO 9 136.67 20.616 6.872 120.82 152.51 110 170 MET+ISO 11 129.09 23.856 7.193 113.06 145.12 100 170 MET 11 118.18 18.878 5.692 105.50 130.86 80 150 K 11 130.00 24.495 7.385 113.54 146.46 100 190 Total 42 128.10 22.332 3.446 121.14 135.05 80 190
Tests of Normality
Group Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic Df Sig. Berat Jantung (BJ) ISO .186 9 .200* .927 9 .453
MET+ISO .212 11 .180 .894 11 .155 MET .189 11 .200* .958 11 .741 K .251 11 .052 .858 11 .054
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction
73 !
! !
73
Test of Homogeneity of Variances Berat Jantung (BJ)
Levene Statistic df1 df2 Sig. .187 3 38 .905
ANOVA Berat Jantung (BJ)
Sum of Squares df Mean Square F Sig. Between Groups 1793.074 3 597.691 1.218 .317 Within Groups 18654.545 38 490.909 Total 20447.619 41
Descriptives BJ /PT
N Mean Std.
Deviation Std. Error 95% Confidence Interval for Mean
Minimum Maximum Lower Bound Upper Bound ISO 9 6.3489 1.00026 .33342 5.5800 7.1178 4.94 7.87 MET+ISO 11 5.8136 1.08955 .32851 5.0817 6.5456 4.45 7.72 MET 11 5.2864 .73816 .22256 4.7905 5.7823 3.80 6.43 K 11 5.9555 1.10354 .33273 5.2141 6.6968 4.73 8.67 Total 42 5.8274 1.02829 .15867 5.5069 6.1478 3.80 8.67
74 !
! !
74
Tests of Normality
Group Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig. BJ /PT ISO .171 9 .200* .947 9 .660
MET+ISO .200 11 .200* .895 11 .160 MET .119 11 .200* .974 11 .928 K .179 11 .200* .870 11 .078
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction
Test of Homogeneity of Variances BJ /PT
Levene Statistic df1 df2 Sig. .453 3 38 .717
75 !
!
ANOVA BJ /PT
Sum of Squares df Mean Square F Sig. Between Groups 5.850 3 1.950 1.976 .134 Within Groups 37.502 38 .987 Total 43.352 41
Descriptives BJ/BB
N Mean Std.
Deviation Std. Error 95% Confidence Interval for Mean
Minimum Maximum Lower Bound Upper Bound ISO 9 5.2000 .97848 .32616 4.4479 5.9521 3.55 6.52 MET+ISO 11 4.5645 .68238 .20575 4.1061 5.0230 3.70 6.07 MET 11 4.5518 .79004 .23820 4.0211 5.0826 3.64 5.91 K 11 5.0018 .93065 .28060 4.3766 5.6270 4.00 7.31 Total 42 4.8119 .86091 .13284 4.5436 5.0802 3.55 7.31
76 !
!
Tests of Normality
Group Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig. BJ/BB ISO .197 9 .200* .939 9 .566
MET+ISO .178 11 .200* .934 11 .448 MET .204 11 .200* .896 11 .164 K .185 11 .200* .860 11 .058
*. This is a lower bound of the true significance. a. Lilliefors Significance Correction
Test of Homogeneity of Variances BJ/BB
Levene Statistic df1 df2 Sig.
.348 3 38 .791
ANOVA BJ/BB
Sum of Squares df Mean Square F Sig. Between Groups 3.169 3 1.056 1.475 .237 Within Groups 27.219 38 .716
Total 30.388 41
77 !
!
Lampiran 6. Biodata Mahasiswa
Identitas
Nama : Ihsan Fadilah
NIM : 22010110120066
TTL : Kotabumi, 18 Oktober 1992
Jenis Kelamin : Laki-laki
Alamat : Jalan Citra H30 Graha Estetika, Banyumanik, Semarang
Nomor Telp. : (024) 7463577
Nomor Ponsel : +6285279343000
E-mail : [email protected]
Riwayat Pendidikan Formal
1. TK : TK Tunas Harapan, Lampung Utara Lulus tahun : 1998
2. SD : SDN 4 Tanjungaman, Lampung Utara Lulus tahun : 2004
3. SMP : SMPN 7 Kotabumi, Lampung Utara Lulus tahun : 2007
4. SMA : SMAN 2 Bandarlampung Lulus tahun : 2010
5. FK Undip, masuk tahun : 2010
Keanggotaan Organisasi
1. Kelompok Studi Mahasiswa FK Undip Tahun 2010 s.d 2014
2. Asisten Mahasiswa Bagian Anatomi FK Undip Tahun 2012 s.d 2014
3. Pengabdian Masyarakat BEM FK Undip Tahun 2011 s.d 2013
4. Asisten Mahasiswa Bagian Kimia FK Undip Tahun 2011 s.d 2012
5. Rohis SMAN 2 Bandarlampung Tahun 2007 s.d 2010
6. Karya Ilmiah Remaja SMAN 2 Bandarlampung Tahun 2007 s.d 2009
7. Kesenian OSIS SMPN Kotabumi Tahun 2005 s.d 2006
Pengalaman Penelitian
1. Yoghurt Kacang Tanah (Arachis hypogaea) sebagai Inovasi Pangan Sehat
Anti-osteoporosis: Sebuah Studi Eksperimental pada Tikus Wistar Model
Osteoporosis, 2014.
78 !
! !
78
2. Prevalensi Infeksi Cacing Cambuk (Trichuris trichiura) dan Cacing Tambang
(Necator americanus dan Ancylostoma duodenale) pada Ibu Hamil di Kota
Semarang, 2013-2014.
3. Analisis Genotype-Phenotype pada Penderita dan Karier Penderita Leber
Hereditary Optic Neuropathy di Indonesia, 2012.
4. Efek Pemberian Yoghurt Kacang Tanah (Phaseolus vulgaris) terhadap Profil
Lipid Serum dan Jumlah Coliform serta Lactobacilli Feses pada Tikus
Dislipidemia, 2011.
Pengalaman Presentasi dan Mengikuti Lomba Karya Ilmiah
1. Yoghurt Kacang Tanah (Arachis hypogaea) sebagai Inovasi Pangan Sehat
Anti-osteoporosis: Sebuah Studi Eksperimental pada Tikus Wistar Model
Osteoporosis. Direktorat Penelitian dan Pengabdian kepada Masyarakat
Ditjen Pendidikan Tinggi Kementerian Pendidikan Nasional. [Penelitian
Didanai]
2. Potensi Gen Antibodi PreS2 dalam Vektor Adenovirus melalui Microneedle
Patch sebagai Vaccinotherapy Hepatitis B dan Karsinoma Hepatoseluler.
FKK Universitas Muhammadiyah Jakarta. [Juara 1 Poster Ilmiah - Nasional]
3. Efek Pemberian Metformin terhadap Hipertrofi Miosit dan FIbrosis
Interstisial Jantung pada Mencit Pasca-Infark Miokardium yang Diinduksi
dengan Isoproterenol. Bidang Riset Himpunan Mahasiswa Kedokteran
Umum Undip. [Juara 3 Proposal Penelitian - Program Studi]
4. Mycospray Berbasis Aspergillus niger Entomopatogenik: Sebuah Inovasi
Pengontrolan Resistensi dan Populasi Aedes aegypti dalam Upaya
Pengendalian Dengue. Departemen Riset BEM FK KM Undip. [Juara 1
Proposal Penelitian - Fakultas]
5. Yoghurt Kacang Tanah (Arachis hypogaea) sebagai Inovasi Pangan Sehat
Anti-osteoporosis: Sebuah Studi Eksperimental pada Tikus Wistar Model
Osteoporosis. Departemen Riset BEM FK KM Undip. [Juara 2 Proposal
Penelitian - Fakultas]
79 !
! !
79
6. Evidence-Based Medicine: Tribendimidine sebagai Obat Alternatif Terbaru
untuk Terapi Ascariasis. Badan Analisis dan Pengembangan Ilmiah Nasional
(BAPIN)-Ikatan Senat Mahasiswa Kedokteran Indonesia (ISMKI) beserta FK
Universitas Padjajaran. [Finalis 6 Besar Gagasan Tertulis - Nasional]
7. Mycospray Berbasis Aspergillus niger Entomopatogenik: Sebuah Inovasi
Pengontrolan Resistensi dan Populasi Aedes aegypti dalam Upaya
Pengendalian Dengue. Himpunan Mahasiswa Kedokteran Umum Undip.
[Juara 1 Gagasan Tertulis - Nasional]
8. Potensi Gen Antibodi PreS2 dalam Vektor Adenovirus melalui Microneedle
Patch sebagai Vaccinotherapy Hepatitis B dan Karsinoma Hepatoseluler.
Himpunan Mahasiswa Kedokteran Umum Undip. [Juara 3 Gagasan Tertulis-
Nasional]
9. Curcumin in Curcuma longa as Inflammoregulator to Prevent
Carcinogenesis of Colitis-associated Colorectal Cancer Promoted by
Commensal pks+ Escherichia coli. FK Universitas Indonesia. [Juara ke-5
Literature Review - Internasional]
10. Efek Pemberian Yoghurt Kacang Merah (Phaseolus vulgaris) terhadap Profil
Lipid Serum dan Jumlah Coliform serta Lactobacilli Feses pada Tikus
Dislipidemia. FK Udayana. [Juara 3 Penelitian - Nasional]
11. Potensi Antibodi PreS2 dalam Vektor Adenovirus melalui Microneedle Patch
sebagai Vaccinotherapy Hepatitis B dan Karsinoma Hepatoseluler. FK
Udayana. [Finalis 10 Besar Poster Ilmiah - Nasional]
12. Efek Pemberian Yoghurt Kacang Tanah (Arachis hypogaea) terhadap Kadar
C-Telopeptida Serum, Kadar Alkali Fosfatase Serum dan Gambaran
Histopatologi Tulang pada Tikus Ovariektomi Model Osteoporosis. Bidang
Riset Himpunan Mahasiswa Kedokteran Umum Undip. [Juara 1 Proposal
Penelitian - Program Studi]
13. Potensi Idebenone untuk Optimalisasi Fungsi Mitokondria pada Penderita
Leber Hereditary Optic Neuropathy (LHON). FK Universitas Sriwijaya.
[Finalis 10 Besar Gagasan Tertulis - Nasional]
80 !
! !
80
14. Analisis Genotype-Phenotype pada Penderita dan Karier Leber Hereditary
Optic Neuropathy di Indonesia. FK Undip. [Penelitian didanai]
15. Efek Pemberian Yoghurt Kacang Merah (Phaseolus vulgaris) terhadap Profil
Lipid Serum dan Jumlah Coliform serta Lactobacilli Feses pada Tikus
Dislipidemia. Direktorat Penelitian dan Pengabdian kepada Masyarakat
Ditjen Pendidikan Tinggi Kementerian Pendidikan Nasional. [Penelitian
Didanai]
16. Efek Pemberian Yoghurt Kacang Merah (Phaseolus vulgaris) terhadap Profil
Lipid Serum dan Jumlah Coliform serta Lactobacilli Feses pada Tikus
Dislipidemia. Fakultas Teknik Undip. [Juara 1 Proposal Penelitian -
Universitas]